Chaithanya, P. K., Maniar, V., Taran, R., Kothari, R. K., Kandappan, V., Nagarkar, R. V., Trivedi, N. N., Thanky, A. H., R, A. K. M., Nemade, B. T., Manillapalli, G., Shrivastav, S. P., Kalloli, M. K. V., Voonna, P., Rajpurohit, S., Kikani, A. J., Saresa, H., Rajani, A., Bunger, D., Chaturvedi, A. (2026). Efficacy, safety, and immunogenicity of pertuzumab biosimilar versus reference pertuzumab in combination with trastuzumab and docetaxel in HER2-positive metastatic breast cancer: A randomized, double-blind, multicenter, parallel group, phase III clinical trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1047